Interactions on record — worth a quick check against your medications. Check your meds →
Dietary supplement

Kyo-Dophilus One Per Day Ingredients & Drug Interactions

by Kyo-Dophilus

Capsule Category: Non-nutrient/non-botanical
Most serious interaction: Moderate
The interaction bottom line Most serious interaction: Moderate

Kyo-Dophilus One Per Day is a dietary supplement by Kyo-Dophilus with 3 active ingredients. Its ingredients are commonly taken for digestive health and regularity, irritable bowel syndrome (ibs), diarrhea (including antibiotic-related).Based on those ingredients, 182 medications have a known interaction with it, the most serious rated moderate. The ingredients most likely to interact are Bifidobacterium longum, Bifidobacterium bifidum, Lactobacillus gasseri. Use the checker below to test your specific medication, or read the full HelloPharmacist Interaction Report.

HelloPharmacist Scorecard of Kyo-Dophilus One Per Day by Kyo-Dophilus

Our pharmacy team’s full take, with four database checks built into the cards below — a summary of what is known, not a grade of the product itself.

From our pharmacy team — supplement deep dive

What’s inside

Low disclosure
Ingredient Transparency · database check
Low

Most active ingredients don't disclose an individual amount — you can't tell how much of each you're getting.

Why this rating?
  • The label discloses an exact amount for 0 of its 3 active ingredients.
  • “Proprietary Blend (Non-Nutrient/Non-Botanical)” is a proprietary blend — the label doesn't break down how much of each component you get.

Kyo-Dophilus One Per Day has three active probiotic ingredients: Bifidobacterium longum, Bifidobacterium bifidum, and Lactobacillus gasseri. These are live bacteria designed to support your gut flora.

The product also contains inactive ingredients — gelatin, potato starch, and silica — which serve as a capsule and flow agents.

Does it work?

Moderate evidence
Evidence for Intended Use · database check
By FDA rules, dietary supplements can’t claim to treat, cure, or prevent disease — so labels speak in careful marketing language. We discern each product’s intended use from its name, label claims, and label statements, then grade the clinical evidence for that use. How these ratings are computed
Moderate

Some clinical evidence supports this product's ingredients for its stated purpose, but it isn't conclusive.

Why this rating?
  • The label markets this product for: promote healthy intestinal function and immunity.
  • We looked for evidence on: Antibiotic-associated diarrhea, Diarrhea, Irritable bowel syndrome (IBS), Constipation, Abdominal pain, Dyspepsia — and 4 related terms.
  • The strongest evidence on file: Bifidobacterium Bifidum is rated "Possibly Effective" for Respiratory tract infections (Natural Medicines).
  • Also on file: Bifidobacterium Bifidum is rated "Possibly Effective" for Irritable bowel syndrome (IBS).
  • Also on file: Bifidobacterium Bifidum is rated "Insufficient Reliable Evidence To Rate" for Antibiotic-associated diarrhea, Common cold, Constipation, Radiation-induced diarrhea, and more.

The evidence for what these probiotics can do is mixed. Bifidobacterium bifidum shows possibly effective evidence for irritable bowel syndrome (IBS) and respiratory tract infections.

However, for Bifidobacterium longum and Lactobacillus gasseri, the data we have rates them insufficient to say whether they work for the conditions listed — which include allergic rhinitis, asthma, anxiety, and diarrhea. If you're considering this for a specific health goal, talk with your pharmacist about what the current evidence actually supports.

How safe is it?

Well-documented data
Safety Information · database check
Well characterized

Adverse-effect, pregnancy, and general safety data are on file for most of these ingredients.

Why this rating?
  • We hold adverse-effect (side-effect) data for 3 of the 3 matched ingredients.
  • Pregnancy & breastfeeding safety ratings cover 3 of 3.
  • General safety write-ups exist for 3 of 3.
  • Remember: this measures how much safety information exists. Thin data is not the same as being safe.

These probiotics are generally well tolerated in healthy people, but caution is warranted if you're seriously ill, have a weakened immune system, or are critically ill — rare cases of bloodstream infection (bacteremia) have been reported in such patients. Common side effects are rare but may include abdominal discomfort, bloating, flatulence, or constipation.

One person in a trial reported a dry cough. Safety data are limited, so use this supplement only under your doctor's guidance, especially if you're breastfeeding — there isn't enough information to know either way, so check with your doctor first.

Meds to double-check

Moderate interaction found
Known Interaction Concern · database check
Moderate identified

The most serious documented interaction for these ingredients is Moderate. Check your medications for a personalized result.

Why this rating?
  • 3 of the 3 matched ingredients can interact with medications — Bifidobacterium Bifidum, Bifidobacterium Longum, Lactobacillus Gasseri.
  • The most serious interaction on file is rated Moderate.
  • For scale: 182 individual medications appear in the full list. A big number alone doesn't make a product dangerous — what matters is whether YOUR medication is on it, so run yours through the interaction checker on this page.

Separate this probiotic from antibiotic drugs (Moderate interaction) — space them several hours apart so the antibiotics don't kill the live organisms. Check your exact prescriptions with the tool on this page to confirm timing.

Check your own medication Run your meds through the checker above

The bottom line

Scorecard at a glanceFormula with limited ingredient disclosure with some supporting evidence for its stated purpose. Moderate medication interactions have been identified, and safety information is well characterized.

Kyo-Dophilus One Per Day is a multi-strain probiotic that works best when separated from antibiotic drugs. If you're taking an antibiotic, talk to your pharmacist about timing.

It may help with IBS or respiratory infections, but evidence for other uses is still being studied. Use it only if you're in good health and under a doctor's care if you have a compromised immune system.

Educational only — not medical advice; always confirm with your pharmacist. Our editorial policy · How we use AI

Assessment coverage: 3 of 3 active ingredients matched to our full ingredient reviews (monographs). Based on the product label dated Mar 25, 2015.

This Scorecard evaluates available label information, ingredient evidence, and known medication-safety considerations. It does not independently verify product identity, purity, potency, contamination, or manufacturing quality. How these ratings are computed

At a glance

General information

Key facts about Kyo-Dophilus One Per Day, straight from the product label.

Brand Kyo-Dophilus
Barcode (UPC) 023542607438
Net contents 30 Capsule(s)
Market status On market
Date entered into DSLD Mar 25, 2015
DSLD ID 42442
Product type Non-nutrient/non-botanical
Supplement form Capsule
Dietary claims / uses All Other, Structure/Function
Intended target group(s) Adult (18 - 50 Years), Children (All), Gluten Free, Dairy Free, Sugar Free
From the label
Everything in this section is reproduced from the manufacturer’s own product label — it’s the label speaking, not HelloPharmacist. We show it so you can see exactly what the maker states; we don’t verify or endorse those statements.

Supplement Facts

The label details for Kyo-Dophilus One Per Day by Kyo-Dophilus, sourced from the NIH Dietary Supplement Label Database.

Supplement Facts

Daily Value (DV) Target Group(s):
Adults and children 4 or more years of age
Minimum serving Sizes:
0.5 Capsule(s)
Maximum serving Sizes:
1 Capsule(s)
UPC/BARCODE
023542607438
IngredientAmount% DV
Bifidobacterium longum0 NP--
Bifidobacterium bifidum0 NP--
Proprietary Blend (Non-Nutrient/Non-Botanical)0 NP--
Lactobacillus gasseri0 NP--

Other ingredients: Gelatin, Potato Starch, Silica

Tap any ingredient to jump to its full detail below.

Label statements
These statements are the manufacturer’s wording, reproduced from the product label — the label is saying it, not HelloPharmacist. We don’t verify or endorse them.
Brand IP Statement(s)

KYO-DOPHILUS(R) One Per Day is formulated with three specially cultured, non-dairy, heat-stable, stomach aid resistant, human strains of beneficial probiotics in a convenient one-per-day capsule. This Friendly Trio(TM) gives you relief from the inconvenience caused by bad bacteria.

FREE OF: preservatives, sugar, sodium, dairy, yeast, soy, gluten, artificial colors and flavors.

General Statements

Take Kyo-Dophilus during and after a cycle of medication, when you travel, and everyday to boost immunity, promote healthy intestinal function and general well-being.Guaranteed stable at time of consumption.

Promotes Healthy Intestinal Function Digestion & Immune

Formulation

Dairy Free.

FDA Disclaimer Statement

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

Precautions

TAMPER RESISTANT CAP AND SEAL: Do not use if cap drop ring or printed inner seal is broken or missing.

Keep out of reach of children.

Seals/Symbols

GMP Certified

FDA Statement of Identity

PROBIOTIC SUPPLEMENT

Suggested/Recommended/Usage/Directions

SUGGESTED USE: Take one capsule for adults (1/2 capsule for children under four) with a meal once daily. For infants, sprinkle 1/2 capsule on food or in juice.

Storage

Store in a cool, dry place with cap tight.

Refrigeration not required.

General

L607A43E

See for yourself

Kyo-Dophilus One Per Day by Kyo-Dophilus label

The label scan from the NIH Dietary Supplement Label Database. Tap to enlarge.

What’s inside

The Ingredients in Kyo-Dophilus One Per Day by Kyo-Dophilus

These are the 3 active ingredients this product is made of. Select any to open its full monograph.

Serving size0.5 Capsule(s) Dosage formCapsule Amounts shown are per serving.

Most supplement products combine several ingredients, and a medication can interact with the product through any one of them. Each ingredient below shows whether it has known drug interactions.

Proprietary Blend (Non-Nutrient/Non-Botanical)

0 NP per serving

Other (inactive) ingredients: Gelatin, Potato Starch, Silica. These complete the product’s ingredient list but are not active constituents.

Interaction report

Kyo-Dophilus One Per Day by Kyo-Dophilus Drug Interactions

Want to check YOUR meds against Kyo-Dophilus One Per Day?

Ask about interactions with your drugs in plain English — “Can I take it with lisinopril?” — and we find you the answer in seconds, ingredient by ingredient.

Go to the checker
182Drugs
182 Moderate

Ingredients driving the most interactions

Each ingredient & the kinds of drugs it affects

For each ingredient in Kyo-Dophilus One Per Day with known interactions, here are the types of medications they can affect. Open any type for the detail — or search your exact drug in the checker above.

Bifidobacterium longum1 drug type · 182 drugs

Antibiotic Drugs

Theoretically, taking Bifidobacterium longum with antibiotic drugs might decrease the effectiveness of B. longum.
Since B. longum preparations usually contain live and active organisms, simultaneously taking antibiotics might kill a significant number of the organisms. Tell patients to separate administration of antibiotics and B. longum preparations by at least 2 hours.

Likelihood Probable Evidence D

Bifidobacterium bifidum1 drug type · 182 drugs

Antibiotic Drugs

Theoretically, taking Bifidobacterium. bifidum with antibiotic drugs might decrease the effectiveness of B. bifidum.
Since B. bifidum preparations usually contain live and active organisms, simultaneously taking antibiotics might kill a significant number of the organisms. Tell patients to separate administration of antibiotics and B. bifidum preparations by at least 2 hours.

Likelihood Probable Evidence D

Lactobacillus gasseri1 drug type · 182 drugs

Antibiotic Drugs

Theoretically, taking Lactobacillus gasseri with antibiotic drugs might decrease the effectiveness of L. gasseri.
Lactobacillus gasseri preparations usually contain live and active organisms. Therefore, simultaneously taking antibiotics might kill a significant number of the organisms. Tell patients to separate administration of antibiotics and L. gasseri preparations by at least two hours.

Likelihood Probable Evidence D
The maker

Brand information

Manufacturer and brand details for Kyo-Dophilus One Per Day, from the product label.

Kyo-Dophilus

See all Kyo-Dophilus products
Name
Wakunaga of America Co., Ltd.
Street Address
23501 Madero
City
Mission Viejo
State
CA
ZipCode
92691
Web Address
www.kyolic.com
Pharmacist Counseling Corner

Kyo-Dophilus One Per Day by Kyo-Dophilus: Common Questions

Does Kyo-Dophilus One Per Day by Kyo-Dophilus interact with any medications?
Yes. Based on its ingredients, Kyo-Dophilus One Per Day has a known interaction with 182 medications. Use the checker to see how it interacts with a specific drug.
How can one product interact with so many drugs?
Kyo-Dophilus One Per Day contains 3 active ingredients, and an interaction can come from any of them. We check every ingredient, combine the results into one list per medication, and show which ingredient and mechanism is responsible.
Where does this information come from?
The product label data comes from the NIH Dietary Supplement Label Database (DSLD); the interaction data is built on the Natural Medicines database and reviewed by HelloPharmacist pharmacists.
Can I take Kyo-Dophilus with my antibiotic?
Not at the same time. Since these are live bacteria, antibiotics will kill them and make the probiotic ineffective. Space them out — your doctor or pharmacist can recommend the right timing, usually a few hours apart.
What does this probiotic actually do?
Bifidobacterium bifidum may help with irritable bowel syndrome and respiratory infections, but Bifidobacterium longum and Lactobacillus gasseri don't have strong evidence yet for the conditions listed. Talk with your pharmacist about whether it fits your specific needs.
Is it safe if I have a weak immune system?
Caution is needed if you're seriously ill or immune-compromised — there are rare reports of bloodstream infections in critically ill patients. Use only under your doctor's guidance if that applies to you.
Can I take this while breastfeeding?
There isn't enough safety data to know for sure. Check with your doctor or pharmacist before using it while breastfeeding — they can weigh the pros and cons for you.
What side effects might I notice?
Most people have none. Rarely, some report bloating, flatulence, abdominal discomfort, or constipation. One person in a trial reported a dry cough. If you notice anything unusual, let your pharmacist know.

Written and reviewed by the HelloPharmacist editorial staff. Our editorial policy

Not sure if Kyo-Dophilus One Per Day is safe with your meds?

Our pharmacists answer your medication & supplement questions — free.

Ask a pharmacist

Label information is sourced from the NIH Dietary Supplement Label Database and reflects the product version on file; always read your actual product label. This page is for education only and is not a substitute for professional medical advice. Confirm with your pharmacist or doctor before combining supplements and medications.

Kyo-Dophilus One Per Day label
Sources

Sources & How We Checked

Kyo-Dophilus One Per Day's label data comes from the NIH Dietary Supplement Label Database; the ingredient interaction data is from the Natural Medicines database, reviewed by our pharmacists.

Content is written and reviewed by licensed HelloPharmacist pharmacists. See our data sources and editorial standards for how this information is built and checked.

The 40 references behind this product’s interaction data

Every citation that drives the interaction findings for this product’s ingredients, from the evidence-graded Natural Medicines (TRC Healthcare) database. Open an ingredient to browse its citations — links open the study on PubMed or the publisher’s site.

Bifidobacterium Longum 21 references
  1. Ha GY, Yang CH, Kim H, Chong Y. Case of sepsis caused by Bifidobacterium longum. J Clin Microbiol 1999;37:1227-8.
  2. Pierce A. The American Pharmaceutical Association Practical Guide to Natural Medicines. New York: The Stonesong Press, 1999:19.
  3. Xiao JZ, Takahashi S, Odamaki T, et al. Antibiotic susceptibility of bifidobacterial strains distributed in the Japanese market. Biosci Biotechnol Biochem. 2010;74(2):336-42. PubMed
  4. Rautava S, Kainonen E, Salminen S, Isolauri E. Maternal probiotic supplementation during pregnancy and breast-feeding reduces the risk of eczema in the infant. J Allergy Clin Immunol. 2012;130(6):1355-60. PubMed
  5. Pruccoli G, Silvestro E, Pace Napoleone C, Aidala E, Garazzino S, Scolfaro C. Are probiotics safe? Bifidobacterium bacteremia in a child with severe heart failure. Infez Med. 2019;27(2):175-178.
  6. Pellonperä O, Vahlberg T, Mokkala K, et al. Weight gain and body composition during pregnancy: a randomised pilot trial with probiotics and/or fish oil. Br J Nutr. 2020 Nov 4:1-11. PubMed
  7. Pellonperä O, Mokkala K, Houttu N, et al. Efficacy of fish oil and/or probiotic intervention on the incidence of gestational diabetes mellitus in an at-risk group of overweight and obese women: A randomized, placebo-controlled, double-blind clinical trial PubMed
  8. Shahriari A, Karimi E, Shahriari M, Aslani N, Khooshideh M, Arab A. The effect of probiotic supplementation on the risk of gestational diabetes mellitus among high-risk pregnant women: A parallel double-blind, randomized, placebo-controlled clinical trial PubMed
  9. Esaiassen E, Hjerde E, Cavanagh JP, Simonsen GS, Klingenberg C; Norwegian Study Group on Invasive Bifidobacterial Infections. Bifidobacterium bacteremia: Clinical characteristics and a genomic approach to assess pathogenicity. J Clin Microbiol. 2017;55(7) PubMed
  10. Enomoto T, Sowa M, Nishimori K, et al. Effects of bifidobacterial supplementation to pregnant women and infants in the prevention of allergy development in infants and on fecal microbiota. Allergol Int 2014;63(4):575-85. PubMed
  11. US Food and Drug Administration (FDA). Dear Healthcare Provider Letter: Warning Regarding Use of Probiotics in Preterm Infants. September 2023. Available at: https://www.fda.gov/media/172606/download?attachment. Accessed November 1, 2023.
  12. Pillai A, Tan J, Paquette V, Panczuk J. Does probiotic bacteremia in premature infants impact clinically relevant outcomes? A case report and updated review of literature. Clin Nutr ESPEN. 2020;39:255-259. PubMed
  13. Sabaté JM, Iglicki F. Effect of Bifidobacterium longum 35624 on disease severity and quality of life in patients with irritable bowel syndrome. World J Gastroenterol 2022;28(7):732-744.
  14. Malaguarnera M, Greco F, Barone G, Gargante MP, Malaguarnera M, Toscano MA. Bifidobacterium longum with fructo-oligosaccharide (FOS) treatment in minimal hepatic encephalopathy: a randomized, double-blind, placebo-controlled study. Dig Dis Sci 2007;52(11) PubMed
  15. Zbinden A, Zbinden R, Berger C, Arlettaz R. Case series of Bifidobacterium longum bacteremia in three preterm infants on probiotic therapy. Neonatology 2015;107(1):56-9.
  16. Tamaki H, Nakase H, Inoue S, et al. Efficacy of probiotic treatment with Bifidobacterium longum 536 for induction of remission in active ulcerative colitis: A randomized, double-blinded, placebo-controlled multicenter trial. Dig Endosc 2016;28(1):67-74.
  17. Bertelli C, Pillonel T, Torregrossa A, et al. Bifidobacterium longum bacteremia in preterm infants receiving probiotics. Clin Infect Dis 2015;60(6):924-7. PubMed
  18. Esaiassen E, Cavanagh P, Hjerde E, Simonsen GS, Støen R, Klingenberg C. Bifidobacterium longum subspecies infantis bacteremia in 3 extremely preterm infants receiving probiotics. Emerg Infect Dis 2016;22(9):1664-6.
  19. Tena D, Losa C, Medina MJ, Sáez-Nieto JA. Peritonitis caused by Bifidobacterium longum: case report and literature review. Anaerobe 2014;27:27-30. PubMed
  20. Sangkanjanavanich S, Pradubpongsa P, Mitthamsiri W, Sangasapaviliya A, Boonpiyathad T. Bifidobacterium infantis 35624 efficacy in patients with uncontrolled asthma: A randomized placebo-controlled trial. Ann Allergy Asthma Immunol 2022;129(6):790-792. PubMed
  21. Wilson HL, Ong CW. Bifidobacterium longum vertebrodiscitis in a patient with cirrhosis and prostate cancer. Anaerobe 2017;47:47-50. PubMed

See these in context on the Bifidobacterium Longum monograph →

Bifidobacterium Bifidum 7 references
  1. Pierce A. The American Pharmaceutical Association Practical Guide to Natural Medicines. New York: The Stonesong Press, 1999:19.
  2. Xiao JZ, Takahashi S, Odamaki T, et al. Antibiotic susceptibility of bifidobacterial strains distributed in the Japanese market. Biosci Biotechnol Biochem. 2010;74(2):336-42. PubMed
  3. Rerksuppaphol S, Rerksuppaphol L. Randomized controlled trial of probiotics to reduce common cold in schoolchildren. Pediatr Int. 2012;54(5):682-7. PubMed
  4. Karamali M, Dadkhah F, Sadrkhanlou M, et al. Effects of probiotic supplementation on glycaemic control and lipid profiles in gestational diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes Metab 2016;42(4):234-41. PubMed
  5. Badehnoosh B, Karamali M, Zarrati M, et al. The effects of probiotic supplementation on biomarkers of inflammation, oxidative stress and pregnancy outcomes in gestational diabetes. J Matern Fetal Neonatal Med. 2018 May;31(9):1128-1136.
  6. Pruccoli G, Silvestro E, Pace Napoleone C, Aidala E, Garazzino S, Scolfaro C. Are probiotics safe? Bifidobacterium bacteremia in a child with severe heart failure. Infez Med. 2019;27(2):175-178.
  7. Esaiassen E, Hjerde E, Cavanagh JP, Simonsen GS, Klingenberg C; Norwegian Study Group on Invasive Bifidobacterial Infections. Bifidobacterium bacteremia: Clinical characteristics and a genomic approach to assess pathogenicity. J Clin Microbiol. 2017;55(7) PubMed

See these in context on the Bifidobacterium Bifidum monograph →

Lactobacillus Gasseri 12 references
  1. Pierce A. The American Pharmaceutical Association Practical Guide to Natural Medicines. New York: The Stonesong Press, 1999:19.
  2. Ramachandran L, Dontaraju VS, Patel K. Lactobacillus-associated spontaneous bacterial peritonitis in a liver cirrhosis patient on probiotics. Cureus. 2020;12(12):e11896. PubMed
  3. Rossi F, Amadoro C, Gasperi M, Colavita G. Lactobacilli infection case reports in the last three years and safety implications. Nutrients. 2022;14(6):1178. PubMed
  4. Ranchal P, Gupta R, Goldberg R, A Lobo S, Pascual A, El Khoury MY. Penicillin-sensitive Lactobacillus jensenii bacteremia. Am J Ther 2021;28(2):e250-e252. PubMed
  5. Grazioli-Gauthier L, Rigamonti E, Leo LA, Martinetti Lucchini G, Lo Priore E, Bernasconi E. Lactobacillus jensenii mitral valve endocarditis: Case report, literature review and new perspectives. IDCases 2022;27:e01401. PubMed
  6. Toprak NU, Bozan T, Yilmaz S, Buyukbayrak EE, Tigen ET. Polymicrobial bacteremia due to Lactobacillus jensenii and Veillonella montpellierensis in a pregnant patient; case report and review of literature. Anaerobe 2022;75:102576. PubMed
  7. Chazan B, Raz R, Shental Y, Sprecher H, Colodner R. Bacteremia and pyelonephritis caused by Lactobacillus jensenii in a patient with urolithiasis. Isr Med Assoc J 2008;10(2):164-5.
  8. Ramos-Coria D, Canto-Losa J, Carrillo-Vázquez D, Carbajal-Morelos L, Estrada-León R, Corona-Rodarte E. Lactobacillus gasseri liver abscess and bacteremia: a case report. BMC Infect Dis 2021;21(1):518. PubMed
  9. Elikowski W, Malek-Elikowska M, Lisiecka M, Bodora A, Wisniewska K, Oko-Sarnowska Z. Lactobacillus gasseri endocarditis on the aortic valve bioprosthesis - a case report. Pol Merkur Lekarski 2017;43(257):220-223.
  10. Esquibel A, Dababneh AS, Palraj BR. Lactobacillus gasseri causing bilateral empyema. Case Rep Infect Dis 2017;2017:4895619.
  11. Tleyjeh IM, Routh J, Qutub MO, Lischer G, Liang KV, Baddour LM. Lactobacillus gasseri causing Fournier's gangrene. Scand J Infect Dis 2004;36(6-7):501-3. PubMed
  12. Dickgiesser U, Weiss N, Fritsche D. Lactobacillus gasseri as the cause of septic urinary infection. Infection 1984;12(1):14-6. PubMed

See these in context on the Lactobacillus Gasseri monograph →

Parts of this content are provided by the Therapeutic Research Center, LLC.

DISCLAIMER: Currently this does not check for drug-drug interactions. This is not an all-inclusive comprehensive list of potential interactions and is for informational purposes only. Not all interactions are known or well-reported in the scientific literature, and new interactions are continually being reported. Input is needed from a qualified healthcare provider including a pharmacist before starting any therapy. Application of clinical judgment is necessary.

© 2021 Therapeutic Research Center, LLC

Keep exploring